ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PTGX vs SYRE // GROSS PROFIT MARGIN

Protagonist Therapeutics Inc. (NASDAQ) VS. Spyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PTGX 4 — SYRE 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. SYRE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PTGX SYRE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -16.70% -20.00% +3.30 PTGX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 0.60% -1.64% +2.24 PTGX /fcf-yield <GO>
Operating Margin -6.00% — — TIE /operating-margins <GO>
Net Profit Margin -5.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 0.00% 17.60% -17.60 SYRE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 26.00 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 5/9 +1.00 PTGX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.8 61.9 -5.10 SYRE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.99 0.89 +0.10 PTGX /macro-sensitivity <GO>
Forward P/E Multiple 31.0x 22.0x +9.00 SYRE /forward-pe <GO>
Enterprise Scale & Market Cap $9.34B $10.33B -$992.9M SYRE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PTGX REV SYRE REV PTGX GROSS % SYRE GROSS % PTGX FCF SYRE FCF
FY 2025 $0 $0 — — $56.1M -$169.3M
FY 2024 $0 $0 — — $182.8M -$157.4M
FY 2023 $0 $886.0K — — -$70.2M -$99.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
SYRE // BETA 0.89